000			03353nam a22004817a 4500
008			221213s20222022 xxu||||| |||| 00| 0 eng d
022			_a1386-341X
024			_a10.1007/s11102-022-01281-5 [doi]
024			_a10.1007/s11102-022-01281-5 [pii]
040			_aOvid MEDLINE(R)
099			_a36261697
245			_aImpact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications.
251			_aPituitary. 25(6):988-996, 2022 Dec.
252			_aPituitary. 25(6):988-996, 2022 Dec.
253			_aPituitary
260			_c2022
260			_fFY2023
260			_p2022 Dec
265			_sppublish
266			_d2022-12-13
520			_aCONCLUSIONS: The majority of null cell adenomas diagnosed under the 2004 WHO classification system are reclassified as gonadotroph or corticotroph adenomas under the 2017 WHO classification system. Rates of progression and recurrence between subtypes are not as different as previously believed at our institution and require a larger cohort to further investigate. Copyright © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
520			_aMETHODS: We constructed a database from all 239 patients who underwent resection of a non-functioning pituitary adenoma between 2003 and 2015 and had at least 5 years of follow-up. Pathologic diagnosis was determined under both the 2004 and 2017 WHO classification systems. We compared the rates of recurrence and progression between subtypes using univariate and multivariate Cox regression analyses.
520			_aPURPOSE: Outcomes of patients with non-functioning pituitary adenomas categorized using the 2004 and 2017 WHO classification systems are understudied. We report outcomes from the University of Virginia of patients with non-functioning pituitary adenomas categorized using both systems.
520			_aRESULTS: Nearly 30% of the tumors in our database were classified as null cell adenomas under the 2004 classification system, whereas only 10% of the tumors were classified as null cell adenomas using the 2017 classification system. Most of these tumors were reclassified as either corticotroph or gonadotroph adenomas. Despite our relatively large cohort and average follow-up of nearly 9 years, we did not detect a significant difference in recurrence and progression between subtypes.
546			_aEnglish
650			_a*ACTH-Secreting Pituitary Adenoma
650			_a*Adenoma
650			_a*Pituitary Neoplasms
650			_aACTH-Secreting Pituitary Adenoma/pa [Pathology]
650			_aAdenoma/pa [Pathology]
650			_aAdenoma/su [Surgery]
650			_aHumans
650			_aPituitary Neoplasms/pa [Pathology]
650			_aPituitary Neoplasms/su [Surgery]
650			_aWorld Health Organization
651			_aMedStar Washington Hospital Center
656			_aOphthalmology Residency
657			_aJournal Article
700			_aElsarrag, Mazin _bMWHC _cOphthalmology Residency _dMD _eResident PGY 2
790			_aAhn J, Chatrath A, Elsarrag M, Jane JA Jr, Kosyakovsky J, Lopes MBS, Patel P, Sokolowski JD, Taylor D, Wu A, Young LC
856			_uhttps://dx.doi.org/10.1007/s11102-022-01281-5 _zhttps://dx.doi.org/10.1007/s11102-022-01281-5
942			_cART _dArticle
999			_c138 _d138